MHC-I SKEWING IN MUTANT CALRETICULIN-POSITIVE MYELOPROLIFERATIVE NEOPLASMS IS COUNTERED BY HETEROCLITIC PEPTIDE CANCER VACCINATION

¹Mathieu Gigoux*, ¹Roberta Zappasodi, ¹Joseph Park, ²Cansu Cimen Bozkus, ¹Levi Mangarin, ¹David Redmond, ¹Svena Verma, ¹Sara Schad, ¹Mariam George, ¹Divya Venkatesh, ¹Amab Ghosh, ¹Zaki Molvi, ³Baransel Kamaz, ³Anna Marneth, ³William Duke, ⁴Matthew Leventhal, ³Max Jan, ³Vincent Ho, ³Gabriela Hobbs, ⁵Trine Knudsen, ⁵Vibe Skov, ⁵Lasse Kjr, ⁶Thomas Larsen, ⁶Dennis Hansen, ³R. Lindsley, ⁵Hans Hasselbalch, ⁷Jacob Grauslund, ⁷Mads Andersen, ⁷Morten Holmstrom, ¹Timothy Chan, ¹Raajit Rampal, ¹Omar Abdel-Wahab, ²Nina Bhardwaj, ³Ann Mullally, ¹Jedd Wolchok, ¹Taha Merghoub. ¹Memorial Sloan Kettering Cancer Center, New York, NY, United States; ²Icahn School of Medicine at Mount Sinai, New York, United States; ³Harvard Medical School, Boston, United States; ⁴Broad Institute, Cambridge, MA, United States; ⁵Zealand University Hospital, Roskilde, Denmark; ⁶Odense University Hospital, Odense, Denmark; ⁷University of Copenhagen, Copenhagen, Denmark

Background The majority of JAK2V617F-negative myeloproliferative neoplasms (MPN) have disease-initiating frameshift mutations in calreticulin (CALR) resulting in a common novel C-terminal mutant fragment (CALRMUT), representing an attractive source of neoantigens for cancer vaccines. However, studies have shown that CALRMUT-specific T cells are rare in CALRMUT MPN patients, but the underlying reasons for this phenomenon are unknown. We speculate that this is due to an increased chance of immune-mediated tumor rejection by individuals expressing one of these MHC-I alleles such that the disease never clinically manifests. As a consequence of this MHC-I allele restriction, we reasoned that CALRMUT MPN patients would not efficiently respond to cancer vaccines composed of the CALRMUT neoantigen, but could do so when immunized with a properly epitope-optimized CALRMUT heteroclitic peptide vaccine approach.

Methods We examined MHC-I allele frequency in CALRMUT MPN patients from two independent cohorts to identify under-represented MHC-I alleles. These MHC-I alleles were assessed for their ability to bind to CALRMUT-derived peptides using NetMHC and were subsequently validated experimentally in healthy donors and in CALRMUT MPN patients having received a CALRMUT cancer vaccine (clinical trial NCT03566446) to determine if these MHC-I were potentiating immunogenicity against the CALRMUT antigen. Epitope-optimized heteroclitic variants of the CALRMUT neoantigen were identified and tested experimentally in vitro in human PBMCs and in vivo in mice for their ability to mount an immune response against the non-modified CALRMUT neoantigen.

Results We observed that MHC-I alleles that present CALRMUT neoepitopes with high affinity are under-represented in CALRMUT MPN patients. Heteroclitic CALRMUT peptides specifically designed for CALRMUT MPN patient MHC-I alleles efficiently elicited a cross-reactive CD8+ T cell response in human PBMC samples otherwise unable to respond to the matched weakly immunogenic CALRMUT native peptides. We also modeled this effect in mice and observed that C57BL/6J mice, which are unable to mount an immune response to the human CALRMUT fragment, can mount a cross-reactive CD8+ T cell response against a CALRMUT-derived peptide upon heteroclitic peptide immunization and this was further amplified by combining the heteroclitic peptide vaccine with blockade of the immune checkpoint molecule PD-1.

Conclusions Our study shows that MHC-I alleles able to present CALRMUT neoepitopes are under-represented in CALRMUT MPN patients, demonstrating that MHC-I haplotype is a major mechanism of passive immune-evasion in

CALRMUT MPN. However, we show that a cancer vaccine composed of heteroclitic variants of the CALRMUT antigen could overcome this limitation.

Ethics Approval Approval was obtained for the use of patient-derived specimens and access to clinical data extracted from patient charts by the Institutional Review Boards at Memorial Sloan Kettering Cancer Center, the Dana-Farber Cancer Institute and the Massachusetts General Hospital, as well as by the Danish Regional Science Ethics Committee.

<http://dx.doi.org/10.1136/jitc-2021-SITC2021.772>